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The identity and functionality of biological membranes are determined by cooperative interaction between
their lipid and protein constituents. Cholesterol is an important structural lipid that modulates fluidity of
biological membranes favoring the formation of detergent-resistant microdomains. In the present study, we
evaluated the functional role of cholesterol and lipid rafts for entry of hepatitis B viruses into hepatocytes. We
show that the duck hepatitis B virus (DHBV) attaches predominantly to detergent-soluble domains on the
plasma membrane. Cholesterol depletion from host membranes and thus disruption of rafts does not affect
DHBV infection. In contrast, depletion of cholesterol from the envelope of both DHBV and human HBV
strongly reduces virus infectivity. Cholesterol depletion increases the density of viral particles and leads to
changes in the ultrastructural appearance of the virus envelope. However, the dual topology of the viral
envelope protein L is not significantly impaired. Infectivity and density of viral particles are partially restored
upon cholesterol replenishment. Binding and entry of cholesterol-deficient DHBV into hepatocytes are not
significantly impaired, in contrast to their release from endosomes. We therefore conclude that viral but not
host cholesterol is required for endosomal escape of DHBV.
Enveloped animal viruses must overcome membrane barri-
ers posed by host cells to deliver their genomes to the respec-
tive replication site. While some viruses achieve this directly at
the plasma membrane, for the majority of viruses, fusion/pen-
etration occurs in the cell interior (30). Evidence for endocy-
tosis as the entry mode of hepatitis B viruses (HBVs) is grow-
ing (11, 14, 36). For duck HBV (DHBV) and primary duck
hepatocytes (PDHs), it has been shown that virus binding is
species and cell type specific, that the preS region of the large
viral envelope protein governs viral entry, that a small number
of virions bind and enter host cells, that viral uptake requires
energy and proceeds with a remarkably slow kinetics, and that
virus trafficking requires dynamic microtubules (11, 14, 36). In
addition, binding of human HBV to host cells is facilitated by
proteoglycans (25, 37). However, major issues such as the
identity and distribution of cellular factors/receptors mediating
virus entry and mode of entry are still unknown (11, 14, 36).
Membrane trafficking and sorting processes are governed by
the lipid composition and organization within membranes.
Membranes of eukaryotic cells contain specialized microdo-
mains called lipid rafts enriched in cholesterol and sphingolip-
ids, with caveolae being the prototype (28, 30). The functional
role of cholesterol and lipid rafts has been studied by choles-
terol depletion or sequestration experiments (29, 31). These
studies revealed that lipid rafts represent specialized platforms
for cellular processes and are exploited for the entry of patho-
gens (30, 39). In addition, it has been shown that viruses not
only depend on cholesterol in the host membranes but can also
rely on the presence of cholesterol in the viral membrane to
overcome host membranes during entry (4).
The envelope of animal viruses is derived from host mem-
branes. The lipid composition of the envelope of paramyxo- or
togaviruses resembles that of the host cell membrane from
which they bud (20, 21). In contrast, other viruses such as
influenza virus or Semliki Forest virus seem to enrich certain
lipids during morphogenesis, as indicated by a lipid composi-
tion that diverges from that of the donor host membranes (26,
33). Hepadnaviruses acquire their envelope at the endoplasmic
reticulum (ER) and are then presumably secreted through the
constitutive secretion pathway (12). A closer look at the mem-
brane of HBV reveals that its cholesterol content is relatively
high compared to the contents of other incorporated lipids (7,
13, 35). The lipid composition thus clearly diverges from that
of ER membranes (24) and suggests an important function for
cholesterol in the viral membrane.
In the present study, we investigated the role of cholesterol
and lipid rafts in membrane-membrane/protein interactions
during hepadnaviral entry. Our data show that the cholesterol
content of the hepadnaviral envelope, but not of host mem-
branes, is a key determinant of the virus infectivity.
MATERIALS AND METHODS
Cell culture. Fetal PDHs were prepared and cultivated as described previously
(8). HBV-infectible HepaRG cells were cultivated as published (15).
Antibodies and drugs. Methyl--cyclodextrin (CD), water-soluble cholesterol,
and mevinolin were obtained from Sigma, reconstituted in H2O or dimethyl
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sulfoxide, and stored at 20°C. Cholera toxin subunit B (CTB) (Sigma) was
reconstituted in H2O and stored at 4°C. We used polyclonal rabbit anti-DHBV
L serum as described previously (8), rabbit anti-DHBV core serum (kindly
provided by L. Cova, France), mouse anti-actin and anti--tubulin (Sigma),
rabbit anti-caveolin (BD Transduction Laboratories, United Kingdom), rabbit
anti-CTB (Sigma), rabbit anti-herpes simplex virus type 1 (HSV-1 [kindly pro-
vided by J. Ku¨hn]), and polyclonal goat anti-vimentin (kindly provided by G.
Tolstonog, Germany). Secondary antibodies conjugated with horseradish perox-
idase were from Dianova (Germany); secondary antibodies conjugated with
Alexa-488 were from Molecular Probes (United Kingdom).
Virus infections. PDHs were infected with DHBV as described previously (8).
HepaRG cells were infected with polyethylene glycol (PEG)-precipitated HBV
from HepG2.2.15 cells as described previously (15). Cells were infected with
HSV and recombinant adenovirus overnight.
Binding of DHBV and CTB to cell surface domains. Cultures were mock
treated or treated with 10 mM CD for 1 h. Then PDHs were washed with cold
medium, drug was readded, and viremic serum was applied. Virus was attached
to the cell surface for 2 h at 4°C. As controls for binding specificity and domain
purification, 10 g/ml CTB or preS peptide-encompassing amino acids 1 to 165
of viral L protein (kindly provided by S. Urban) were used. Cells were either
washed extensively with ice-cold phosphate-buffered saline and harvested or
shifted to 37°C for 30 min. For harvest, cells were scraped in 1 ml ice-cold TNE
buffer (25 mM Tris [pH 7.5], 50 mM NaCl, 5 mM EDTA [pH 7.4]) containing 1%
Triton X-100. Biochemical isolation of lipid rafts was performed as described pre-
viously (6).
For detection of CTB binding on the cellular level, PDHs were treated or not
with 10 mM CD for 1 h at 37°C. Then, 10 g/ml fluorescein isothiocyanate-
labeled CTB was added for 30 min at 37°C. Cells were either fixed with 3.7%
paraformaldehyde or washed and further incubated to study the reversibility of
CD treatment. Pictures were acquired using a confocal laser-scanning micro-
scope (LSM 510 META; Zeiss).
Cholesterol depletion of cells with mevinolin and virus infection. Congenitally
DHBV-infected PDHs were treated with 100 M mevinolin for 24 h and sub-
sequently treated with 10 M mevinolin for a further 48 h. Then supernatants
were harvested and the infectivity of progeny virus was tested. To test the role of
host cholesterol for DHBV entry, PDHs were treated for 24 h with 100 M and
subsequently for 48 h with 10 M mevinolin to inhibit cholesterol biosynthesis
prior to DHBV infection in the presence of the drug. To control the efficacy of
cholesterol depletion, PDHs were infected with HSV 24 h and 48 h after the
commencement of mevinolin treatment.
Add-in assay. Cells were exposed to DHBV at 4°C. After 2 h of binding, cells
were washed three times with phosphate-buffered saline to remove unbound
virus. The plate was transferred to 37°C to allow virus internalization. CD was
added before or after 30 min, 1 h, or 2 h of incubation at 37°C. After 16 h of
further incubation, cells were washed to remove drug and unbound virus. Three
days later, cells were harvested and immunoblotted for L protein.
Cholesterol depletion and replenishment of hepadnaviral particles. Twenty
microliters of DHBV viremic serum or 100 l PEG-precipitated HBV was
incubated for 1 h at 37°C with different concentrations of the drug or H2O in
medium. Viral particles were precipitated with 10% PEG after treatment. Then
PDHs or HepaRG cells were infected with treated virus and productive infection
was tested as described below. For cholesterol replenishment, viral particles were
treated as described above. Then 50 g/ml water-soluble cholesterol was added
and incubation continued for 1 h. Alternatively, CD and cholesterol were added
simultaneously. Particles were precipitated, and their infectivity was tested.
Subcellular fractionation, immunoblotting, immunofluorescence staining,
and DHBV DNA-specific PCR. The subcellular fractionation, immunoblotting,
immunofluorescence staining, and DHBV DNA-specific PCR assays were done
as described previously (8, 38). Signals were quantified after acquisition with a
Fluor-S MultiImager (Bio-Rad, Germany) using Quantity One software.
HBV infection of HepaRG cells. Cells were infected with the above-mentioned
inoculum as described previously (15). Cell culture supernatant was harvested 9
days after inoculation and was tested by enzyme-linked immunosorbent assay for
HBe antigen using a commercial kit (Abbot, United Kingdom).
Electron microscopy. Viral particles were immunoprecipitated with anti-L
antibodies, treated as indicated for 1 h at 37°C, and processed for electron
microscopy as described previously (9, 32).
Density-based gradient ultracentrifugation and DNA-dot blot analysis. An
aliquot of mock-treated or treated viral particles was loaded onto a cesium
chloride gradient ranging from 1.4 g/cm3 to 1.2 g/cm3. Fractions of about 200 l
were collected from the bottom. The fractions were dotted onto a membrane and
hybridized with a DHBV DNA-specific radioactive probe. Signals were acquired
and quantified using a PhosphorImager and AIDA software.
Protease protection assay. Mock- and CD-treated viral particles were digested
with trypsin as described previously (22, 23).
Determination of cholesterol content. The amount of cholesterol was deter-
mined using the Amplex red cholesterol assay kit (Invitrogen) according to the
manufacturer’s instructions. The amount of cholesterol was normalized to the
protein content of the sample.
RESULTS
DHBV preferentially binds to detergent-soluble domains on
hepatocellular membranes. We have previously shown that
endocytic internalization of DHBV requires an unusually long
time period (9, 10) and diverges from that of viruses known to
be taken up by clathrin-mediated endocytosis. Since the time
requirement resembles more closely that of polyomaviruses,
which enter the cells via lipid rafts (2), we assumed that DHBV
uses an analogous entry route. To test this, we first determined
the fraction of DHBV particles binding to lipid rafts on hep-
atocellular membranes. Prior to virus inoculation, cells were
treated or not with 10 mM CD to deplete cholesterol from the
plasma membrane and disrupt lipid rafts. This treatment re-
duced the cholesterol content of the cells by an average of 37%
and led to redistribution of caveolin-1 (marker protein for lipid
rafts) and CTB (known to bind lipid rafts) from the detergent-
insoluble membrane (DIM) fraction to the detergent-soluble
membrane (DSM) fraction (Fig. 1A, lanes 5 and 6). In addi-
tion, disruption of lipid rafts upon cholesterol depletion was
visualized using FITC-labeled CTB and fluorescence micros-
copy (Fig. 1E). CD-treated cells exhibited a smooth and reg-
ular pattern of CTB distribution on the cell membrane, in
marked contrast to the patchy one in untreated cells. Also CTB
uptake into the cells was strongly reduced. Removal of the
drug resulted in partial reformation of the lipid rafts after
about 1 h (Fig. 1E).
CD-treated cells were incubated with viremic serum or a
recombinant peptide encompassing amino acids 1 to 165 of the
viral envelope protein L. After 2 h of incubation at 4°C, cells
were harvested and lysed in a Triton X-100-containing buffer.
DIM were separated from DSM and analyzed for the presence
of viral L protein and DNA by immunoblotting and PCR,
respectively. In both mock- and CD-treated cells, L protein
was enriched to about 60% in DSM fractions, although a small
amount could be detected in the DIM fraction (Fig. 1B, lanes
3 and 4). This slightly increased after cholesterol depletion to
about 75% (Fig. 1B, lanes 5 and 6). Thus, cholesterol depletion
from cellular membranes did not significantly change the mem-
brane partitioning of bound viral particles. The partitioning of
recombinant peptide on hepatocellular membranes was indis-
tinguishable from that of viral particles (Fig. 1B, lanes 7 and 8).
PCR analysis of the same fractions for viral DNA revealed that
the partitioning profile of virions paralleled that of L protein
with about 70% of total viral DNA present in the DSM frac-
tion (Fig. 1C, lanes 3 and 4). These data show that binding of
subviral particles and virions as well as nonparticulate L pro-
tein involves sites preferentially located in nonlipid raft regions
of the hepatocellular plasma membrane.
In order to investigate whether viral particles preattached to
hepatocellular membranes redistribute from DIMs to DSMs or
vice versa upon initiation of membrane mobility, cultures were
warmed for 30 min to 37°C. This warming did not result in a
significant redistribution of attached viral particles (Fig. 1D,
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lanes 5 and 6). The lipid raft marker protein caveolin-1 re-
mained in the DIM fraction during the temperature shift, in-
dicating domain stability and excluding a significant mixing of
domains by lateral diffusion (Fig. 1D, lanes 5 and 6). The data
indicate that viral particles do not first bind to DSMs and then
shift to DIMs or vice versa.
DHBV infection does not depend on cellular cholesterol. To
test the requirement for cellular cholesterol only during
DHBV entry, PDHs were pretreated for 1 h with 10 mM CD.
Afterwards, cells were washed and incubated for 1 h without
the drug before inoculation with DHBV. This washout assay
was performed to ensure that cholesterol was depleted only
from cellular, but not viral, membranes prior to DHBV infec-
tion. Alternatively, CD was present during the inoculation
period overnight, thus acting on both virus and cellular mem-
branes. Infection efficiency was strongly reduced when CD was
present in the medium at the time of inoculation, while it was
not reduced when CD was absent (Fig. 2A). This indicated that
cellular cholesterol is dispensable for virus infection and that
CD presumably acts on the virus itself. To obtain additional
evidence for the cholesterol dependence of infection, we used
viral particles produced from congenitally DHBV-infected
cells treated with mevinolin. This drug inhibits cholesterol bio-
synthesis in the cells, and this should lead to the production of
progeny virus with a reduced cholesterol content (1). Treat-
ment of DHBV-infected PDHs with mevinolin led to a mod-
erate decrease in secreted viral particles as determined by PCR
and immunoblotting (see Fig. S1 in the supplemental mate-
rial). This decrease was taken into account when cells were
infected and the multiplicity of genome equivalents (GE) was
consequently adjusted. Anticore immunoblotting and fluores-
cence of PDHs infected with viral particles from mevinolin-
treated cells show a strong reduction in infectivity of the prog-
eny virus (Fig. 2B), thus indicating that cholesterol in the virus
membrane is required for infectivity of DHBV. However, we
cannot exclude at this stage that mevinolin treatment resulted
in conformational changes of the viral particle which reduced
infectivity.
To determine at which time point upon viral entry choles-
terol became dispensable for infection, we performed an “add-
FIG. 1. DHBV preferentially binds to DSM domains on hepatocytes. (A) CTB was attached to PDHs. DIMs and DSMs were isolated, and
fractions were analyzed for caveolin-1 and CTB by immunoblotting. (B) DHBV or recombinant preS protein (peptide) was attached to PDHs.
DIMs and DSMs were isolated and analyzed by immunoblotting for L protein and caveolin. (C) PCR analysis of the same fractions for DHBV
DNA. PCR was standardized using serial dilutions of a viremic serum with known GE. (D) After DHBV attachment at 4°C, unbound inoculum
was removed and cultures were warmed to 37°C. DIMs and DSMs were isolated and subjected to immunoblot analysis for L and caveolin protein.
(E) PDHs were treated with CD for 1 h at 37°C and then incubated with 10 g/ml FITC-CTB for 30 min at 37°C. Cells were either fixed or washed
to remove unbound ligand and further cultivated for the indicated time periods and then fixed. Cells were analyzed by confocal scanning
microscopy. Bars correspond to 5 m. TX-100, Triton X-100.
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in” assay. Cells were exposed to DHBV at 4°C. Following
removal of the inoculum, internalization of attached virus was
initiated at 37°C and cells were treated at indicated time points
with CD. This assay revealed strong inhibition of infection
when cells were treated during inoculation and up to 30 min
postinternalization compared to the nontreated control (Fig.
2C, lanes 1 to 3). Then L protein amounts gradually increase,
suggesting protection of the virus from the CD treatment.
Cholesterol depletion 2 h after virus internalization only led to
a minor reduction in virus infection (Fig. 2C, lanes 4 to 5).
These findings indicate that internalized DHBV are largely
protected from the antiviral effect of CD, and thus virus entry
depends on a cholesterol-sensitive step very early in infection.
The efficiency of cholesterol depletion from PDHs was con-
trolled by infection experiments using HSV and a recombinant
adenovirus encoding green fluorescent protein (GFP). As ex-
pected, cholesterol-depleted hepatocytes were inefficiently in-
fected by HSV and adenovirus (3, 18) (Fig. 2D and E).
To assess whether DHBV entry depends on host cell cho-
lesterol, PDHs were pretreated with mevinolin for up to 48 h
and subsequently inoculated with DHBV and HSV as a con-
trol. After about 16 h of incubation, the drug and inoculum
were removed. Cells were harvested 3 days later, and lysates
were subjected to immunoblot analysis for core protein.
Mevinolin treatment had no negative effect on DHBV infec-
tion since the core signal in treated cells was comparable to
that of nontreated cells (Fig. 2F, lanes 2 and 3). In contrast, the
permissiveness of PDHs for HSV was strongly reduced 24 and
48 h after inhibition of cholesterol biosynthesis in PDHs (Fig.
2F, lanes 6 to 9).
Taken together, our data show that host cell cholesterol is
dispensable for productive entry of DHBV in PDHs. These
FIG. 2. Cellular cholesterol is dispensable for DHBV infection. (A) PDHs were pretreated with CD. Thereafter, cultures were infected with
DHBV in the presence (CD) or 1 h after removal of the drug (CD1h). Cells were maintained for a further 3 days in medium devoid of drugs
and virus, harvested, and subjected to immunofluorescence (left panel) and immunoblot analysis for core protein and to PCR for viral DNA (right
panel). (B) Congenitally DHBV-infected PDHs were treated or not with mevinolin, and supernatants were harvested. Infectivity of virus progeny
in the supernatants was tested by immunofluorescence (upper panel) and immunoblot (lower panel) analysis for core protein. (C) After DHBV
attachment at 4°C and removal of unbound inoculum, PDHs were treated with CD at indicated time points at 37°C. The lysates were analyzed by
immunoblotting for L; tubulin served as a loading control. (D and E) PDHs were treated, infected with HSV or a recombinant adenovirus encoding
GFP, harvested, and analyzed by immunoblotting for HSV and GFP, respectively. Tubulin served as a loading control. (F) PDHs were treated with
mevinolin to inhibit cholesterol biosynthesis prior to DHBV infection. To control the extent of cholesterol depletion by mevinolin treatment, PDHs
were infected with HSV 24 h and 48 h after inhibition of cholesterol biosynthesis. Immunoblots for DHBV core (left panel) and HSV (right panel)
were performed. Tubulin served as a loading control. h pa, hour postattachment.
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findings are consistent with the notion that DHBV preferen-
tially binds to DSMs. Thus, DHBV entry into hepatocytes is
presumably not mediated to an infection-relevant extent by
lipid rafts.
The cholesterol content of the envelope governs infectivity of
hepatitis B viruses. The data described above indicate that CD
acts on the virus itself and reduces its infectivity. CD selectively
binds cholesterol and depletes it very efficiently from mem-
branes without disturbing other lipids (19). If the envelope-
mediated entry of DHBV is strictly dependent on cholesterol,
CD-treated viral particles should exhibit an altered infectivity.
To investigate this, DHBV-containing serum was treated with
10 mM CD, which reduced the cholesterol content by about
20% or an equivalent amount of H2O as the mock control.
Thereafter, viral particles were pelleted to remove CD and
used for infection experiments. The amount of input virus was
controlled by PCR in this (Fig. 3A) and all following experi-
ments (data not shown). All assays showed an almost complete
loss of virus infectivity upon cholesterol depletion (Fig. 3A to
C). The L immunoblot showed no signal in the case of cultures
inoculated with CD-treated DHBV, in contrast to cultures
inoculated with mock-treated virus, although the amount of
input virus was comparable (Fig. 3A, lanes 2 and 3). The PCR
analysis corroborated these results and showed strongly re-
duced signals in cells infected with cholesterol-depleted viral
particles (Fig. 3B, lanes 2 and 3).
The antiviral effect of CD was dose dependent, as deter-
mined by dose escalation experiments and observed with doses
as low as 2.5 mM (Fig. 3C, lanes 4 to 7). As judged from the
quantification of the core immunoblot, the 50% effective con-
FIG. 3. Cholesterol depletion strongly reduces infectivity of both DHBV and HBV. DHBV viremic serum was treated with CD; viral particles
were pelleted and used as the inoculum. (A) PDHs were harvested 3 days after DHBV infection, and lysates were subjected to immunoblot analysis
for L (upper panel). The amount of input virus was controlled by PCR (lower panel). (B) Replicative intermediates were extracted 3 days after
DHBV infection and assayed by PCR. PCR was standardized using serial dilutions of a viremic serum with known GE. (C) The antiviral effect of
CD is dose dependent. PDHs were infected with DHBV treated with CD at the indicated concentrations. Three days after infection, cells were
harvested and lysates were subjected to immunoblot analysis for viral L and core protein. Vimentin served as a loading control. Quantification of
the core blot signals is shown in the right panel. (D) Cell culture supernatants of HepaRG cells infected with CD-treated HBV were harvested
9 days after infection and analyzed for HBe antigen. The standard deviation from two experiments is shown.
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centration of CD for DHBV was about 2.5 mM (Fig. 3C, right
panel). When higher concentrations were used, infection effi-
ciency decreased to less than 1% at 10 mM compared to that
of the mock-treated control. This indicates that a threshold
cholesterol concentration in the viral membrane is required for
virus infectivity. When a ratio of five CD molecules binding
one cholesterol molecule is assumed (40), CD may deplete up
to 106 cholesterol molecules per viral particle at the highest
concentration used.
To corroborate the results obtained for DHBV, we per-
formed a proof-of-principle experiment using HBV and Hep-
aRG cells. Nine days after infection with CD-treated HBV
particles, cell culture supernatants were analyzed for HBe an-
tigen by enzyme-linked immunosorbent assay. This assay
showed that cholesterol depletion strongly and concentration
dependently reduced infectivity of HBV (Fig. 3D).
Taken together, these data show that cholesterol depletion
of hepadnaviral particles leads to a strong reduction of their
infectivity. The cholesterol requirement for virus infectivity
seems to be a conserved feature of at least human HBV and
DHBV.
Cholesterol depletion alters the morphology of the viral
envelope and buoyant density of viral particles. To investigate
the impact of cholesterol depletion on the overall structural
integrity of viral particles, we performed transmission electron
microscopy (TEM) analysis. DHBV particles were immuno-
captured from viremic serum using an L-specific antiserum,
treated, and analyzed by TEM. In the mock-treated sample,
the envelope of the viral particles attached to the beads is
clearly visible as two thin lines (Fig. 4A, left panel). After
cholesterol depletion with two different CD concentrations,
the appearance of the viral envelope was strongly altered and
seemed to be reduced to one layer (Fig. 4A, middle and right
panels). Particles seem to be collapsed. Otherwise, the overall
structures of the viral particles in CD- and mock-treated sam-
ples were comparable. These findings show that cholesterol
depletion of the viral membrane results in a strong alteration
of its ultrastructural appearance.
As a further control for integrity of the virus envelope, the
topology of envelope protein L was determined. DHBV L
exists in two topologies: half of the L protein has the amino-
terminal preS region located inside the viral particle, and the
other half has the region located outside. This results in pro-
tection of about half of the viral L molecules from protease
digestion. Cholesterol-depleted viral particles did not display
significant changes in the dual-L topology, as judged by com-
parison of tryptic product patterns after limited protease di-
gestion of untreated and CD-treated viral particles (Fig. 4B,
lanes 2 and 5, respectively).
We assumed that the observed ultrastructural changes and
loss of cholesterol result in an altered density of the viral
particles. To test this, cholesterol-depleted viral particles were
FIG. 4. Effect of cholesterol depletion on the ultrastructure of DHBV particles and L topology. (A) Viral particles were immunocaptured to
beads from viremic serum, treated with different CD concentrations, and processed for ultrastructural analysis by TEM. The lower magnifications
show the decoration of beads with viral particles. The ultrastructure of single viral particles is shown at high magnification in the subpanels.
(B) Dual topology of L protein before and after cholesterol depletion of viral particles was determined by protease protection assay. Trypsin-
mediated proteolysis of L protein in the membranes of CD- and mock-treated DHBV particles was monitored by immunoblotting before and after
addition of NP-40.
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subjected to isopycnic gradient ultracentrifugation and frac-
tions were analyzed for the presence of viral DNA by dot blot
analysis. As judged from the DNA dot blot, cholesterol deple-
tion resulted in an increase of viral particle density (Fig. 5A).
The fraction with the highest density presumably contains par-
ticles with a severely altered envelope. This fraction is in-
creased after cholesterol depletion of viral particles compared
to the mock-treated control from about 1% of total counts to
about 8% (Fig. 5B), indicating de-envelopment after choles-
terol depletion. Overall, a shift of cholesterol-depleted virions
to the denser fractions of the gradient was observed. An L
immunoblot of the same fractions showed an increase in sig-
nals in the fractions with lower density (data not shown). This
is consistent with a partial collapse of subviral particles after
cholesterol depletion.
In conclusion, cholesterol in the DHBV membrane is essen-
tial for the density and structure of viral particles.
Partial recovery of DHBV infectivity upon cholesterol re-
plenishment. To investigate the reversibility of cholesterol de-
pletion, we incubated cholesterol-depleted viral particles with
different amounts of water-soluble cholesterol and determined
viral particle density and infectivity. As shown above, viral
particle density increased after cholesterol depletion compared
to that in the mock-treated control (Fig. 6A). Addition of 50
g/ml water-soluble cholesterol to mock-treated particles led
to a slight decrease in particle density, indicating that mock-
treated viral particles were able to incorporate additional cho-
lesterol. Cholesterol replenishment of CD-treated viral parti-
cles led to a partial restoration of viral density to levels
comparable to that of the mock control (Fig. 6A). A significant
fraction of virions shifted to the peak fraction of mock-treated
virus. Thus, cholesterol-depleted viral particles were presum-
ably successfully reloaded with cholesterol, as indicated by a
decrease in their density. In addition, we determined the cho-
lesterol content of CD- and cholesterol treated particles. These
treatments led to a 20% reduction and 5% increase of viral
cholesterol content, respectively.
Infection experiments with the replenished DHBV particles
showed a partial restoration of virus infectivity up to 20% (Fig.
6B and C). After cholesterol replenishment, the amount of
secreted DNA-containing particles in the cell culture superna-
tant after infection increased significantly compared to infection
with CD-treated particles (Fig. 6B). Immunoblotting of the cel-
lular lysates corroborated these results and showed that choles-
terol replenishment of viral particles increased infection efficiency
after CD treatment (Fig. 6C). Electron microscopic analysis of
replenished particles indicates that viral morphology can be par-
tially restored after cholesterol incubation (Fig. 6D).
Taken together, the results show that cholesterol reloading
can at least partially restore density and infectivity of choles-
terol-depleted DHBV, indicating that the cholesterol in the
viral membrane is indispensable for virus infectivity.
FIG. 5. Effect of cholesterol depletion on the buoyant density of DHBV particles. Cholesterol-depleted or mock-treated DHBV particles were
subjected to CsCl2-based density gradient ultracentrifugation. Fractions were collected and analyzed for viral DNA by dot blotting. (A) Dot blot
analysis of fractions for viral DNA. (B) Quantification of the signals from three independent experiments. MCD, methyl--cyclodextrin. Bars
show the standard deviation.
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Cholesterol in the viral envelope is required for endosomal
escape, but not binding and entry of DHBV in PDHs. The
experiments shown above indicate that DHBV entry into hepa-
tocytes depends on the cholesterol content of the virus enve-
lope. To further elucidate this, we investigated the binding and
internalization competence of cholesterol-deficient DHBV
virions and subviral particles as described previously (8). As a
specificity control, cells were pretreated with suramin, which
decreases infection-relevant virus binding (8). Comparison of
the amounts of viral particles attached to PDHs revealed sim-
ilar amounts in the case of cells incubated with cholesterol-
depleted DHBV compared to the control, indicating that CD
treatment of particles did not lead to a significant loss of viral
protein or DNA (Fig. 7A and B, lanes 1 and 2). Attached,
not-yet-internalized viral particles were almost completely re-
moved by trypsin digestion (Fig. 7B, lanes 8 and 9), as shown
previously (8). These results demonstrate that cholesterol in
the virus membrane is not required for binding of DHBV to
hepatocytes. In addition, analysis of the inoculum revealed that
the pattern of viral envelope protein L and DNA did not
change significantly after cholesterol depletion (Fig. 7A and B,
lanes 1 and 2). Determination of the fraction of internalized
viral particles after 1 h and 6 h of entry showed that the amount
of internalized DHBV was not strongly reduced in cholesterol-
depleted DHBV compared to control virus (Fig. 7B, lanes 10
and 11, and Fig. 8A, lanes 4 and 6, respectively). These data
indicate that cholesterol depletion has no detectable influence
on DHBV binding and entry and that the infectivity loss of
cholesterol-depleted virions is presumably due to a postentry
event.
Recent work by others and us suggests that DHBV is inter-
nalized by endocytosis (5, 9, 38). Therefore, we hypothesized
that cholesterol is essential for the membrane-membrane/pro-
tein interaction required for release of DHBV from endo-
somes. To test this, PDHs were inoculated for 6 h with mock-
or CD-treated DHBV. Cells were harvested with trypsin to
FIG. 6. Partial recovery of buoyant density, infectivity, and morphology of DHBV upon cholesterol replenishment. (A) Samples were subjected
to density gradient centrifugation. Fractions were analyzed by DHBV-DNA dot blotting. Quantification of the signals from three independent
experiments is shown. Bars show the standard deviation. (B and C) Viral particles were treated as indicated, PEG precipitated, and used for
infection of PDHs. Three days after infection, cells and cell culture supernatants were harvested and analyzed. (B) Semiquantitative PCR analysis
of viral DNA in cell culture supernatants. PCR was standardized using serial dilutions of a viremic serum with known GE. (C) Immunoblotting
of cellular lysates for viral L and core protein. Tubulin served as a loading control. The right panel shows a quantification of the core immunoblot.
“co” indicates that cholesterol and CD were simultaneously added; “succ” indicates that particles were first treated with CD and then with
cholesterol. (D) Viral particles were pretreated with CD and cholesterol (Chol.) as indicated and prepared for TEM analysis. The ultrastructure
of single viral particles is shown at high magnification.
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remove cell-surface-bound, not-yet-internalized viral particles,
and endosomal and cytosolic fractions were prepared. Purity of
the fractions was controlled by immunoblotting fractions for
endosomal marker caveolin-1 and cytosolic marker Hsc70 (see
Fig. S2 in the supplemental material). Determination of the
amount of viral DNA in the respective subcellular fractions
revealed that similar amounts of mock- or CD-treated virions
were taken up into the endosomal compartments of PDHs.
However, in the cytosolic fraction, viral DNA was only detect-
able in case of cells infected with mock-treated DHBV (Fig.
8A and B, lanes 5 and 7). There was only a barely detectable
amount of viral DNA in the cytosolic fraction of cells inocu-
lated with cholesterol-depleted DHBV. In addition, immuno-
blotting for viral L protein showed that this protein is detect-
able in the endosomal fraction only (Fig. 8C, lanes 3 and 5).
Concanamycin treatment of PDHs prevents the endosomal
escape of incoming DHBV and leads to stabilization of L
protein, as reported previously (9), and was used as a control.
The data indicate that cholesterol-depleted viral particles
were not able to cross the barrier posed by the endosomal
membrane. Thus, viral membrane cholesterol is required for
endosomal escape of the virus into the cytosol.
FIG. 7. Cholesterol-depleted DHBV binds and enters into PDHs. CD- or mock-treated DHBV particles were attached to PDHs. Cells were
harvested with or without trypsin or warmed to 37°C for 1 h after removal of the inoculum. Both inoculum and cell lysates were subjected to
immunoblotting and PCR analysis for viral L protein (A) and DNA (B), respectively. Vimentin served as a loading control. PCR was standardized
with serial dilutions of a viremic serum with known GE.
FIG. 8. Cholesterol depletion impairs endosomal escape of DHBV. PDHs were inoculated with mock- or CD-treated DHBV. Cells were
harvested by trypsin digestion and subjected to subcellular fractionation. The cytosolic (C) and the endosomal (E) fractions were analyzed for
DHBV DNA by PCR. A representative agarose gel image of PCR products (A) and quantification of the PCR signals (B) are shown. Bars indicate
the standard deviations from two independent experiments. C) Anti-L immunoblot of the same fractions. Subcellular fractions of concanamycin-
treated PDHs were included as a control.
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DISCUSSION
Enveloped viruses evolved different mechanisms to over-
come the barriers posed by host membranes during entry (17).
The finding that the endosomal release of incoming cholesterol-
depleted virions is significantly impaired together with the
strong inhibition of infection suggests that viral membrane
cholesterol plays a pivotal role during virus entry. Often, mem-
brane fusion is triggered by the interaction of particular fuso-
genic (glyco-) proteins in the virus envelope with certain lipids
in the membrane. For example, artificial membranes consisting
of phosphatidylcholine, phosphatidylethanolamine, sphingo-
myelin, and cholesterol incubated with the human immunode-
ficiency virus (HIV) fusion protein gp41 fuse optimally at a
35/30/15/20 molar ratio, respectively (16). An analogous situ-
ation might exist during entry of HBVs into host cells. Thus,
alteration of the amount of cholesterol in the hepadnaviral
envelope may comprise its fusion competence and lead to loss
of virus infectivity. In the case of HIV-1, virus-associated cho-
lesterol is essential for the fusion of the virus membrane with
the plasma membrane and it has been suggested that virus
envelope clustering and restructuring upon virus attachment
depend on cholesterol (34). Replenishment of the HIV enve-
lope with cholesterol restored the infectivity of cholesterol-
depleted HIV-1 (4). Cholesterol is thus pivotal for structural
integrity and infectivity of both hepadnaviruses and HIV, two
major human pathogens.
In the case of HIV-1, it has been reported that cholesterol
depletion from both cellular and virus membranes substantially
reduced the permissiveness of cells and led to loss of viral
particle infectivity, respectively (4, 27). In contrast, according
to our data, depletion of cholesterol from host membranes
does not interfere with the permissiveness of hepatocytes for
DHBV. The finding that DHBV preferentially binds to DSMs
on the plasma membrane further strengthens this notion.
Thus, cholesterol dependence provides a novel example for
both conservation of and variation in host factor requirements
by different viruses.
The amount of viral L protein and its dual topology were not
significantly impaired in cholesterol-depleted particles com-
pared to control ones. Thus, it appears that hepadnaviral en-
velope proteins alone are necessary, but insufficient, to induce
membrane fusion and depend on certain lipids, in particular
cholesterol, to exert their function. Consistent with this are the
changes in the ultrastructural appearance of the DHBV enve-
lope upon cholesterol depletion. Loss of infectivity of DHBV
and HBV virions after cholesterol depletion was dose depen-
dent with a 50% effective concentration of about 2.5 mM,
indicating that a certain cholesterol concentration is needed
for the functionality of the virus membrane. Rearrangements
within the entire envelope and/or particular microdomains
necessary for infection appear to be increasingly restricted by
lowering the membrane cholesterol content.
Overall, our data clearly demonstrate that virion-associated
cholesterol is required for structural integrity and infectivity of
hepatitis B viruses. As depicted in the model in Fig. 9, choles-
terol seems to be essential for the membrane-membrane/pro-
tein interaction during the endosomal stage of virus entry. If
this interaction is disturbed, viral particles are presumably not
released from the endosome and degraded. However, the
mechanism(s) by which cholesterol controls endosomal escape
of the incoming virions is currently not clear. Cholesterol-
dependent rearrangements within the virus envelope may be
FIG. 9. Model for cholesterol dependence of DHBV entry into hepatocytes. DHBV infection initiates with attachment of viral particles to
binding sites preferentially located in detergent-soluble domains of the plasma membrane. Following attachment, viral particles are internalized
by endocytosis. Endosomal exit of incoming viral particles strongly depends on the cholesterol content of the virus membrane. Cholesterol
depletion from the virus membrane results in their endosomal entrapment and presumably proteolytic clearance leading to abrogation of infection.
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required for fusion of the virus envelope with the endosomal
membrane. Mutually not exclusive, cholesterol may be re-
quired for the release of capsids out of the endosomal com-
partment subsequent to fusion pore formation.
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